A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Organon and Co
Study ID
NCT07265479
Phase
PHASE3
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
3 Months - 23 Months
Healthy Volunteers
Not accepted

Interventions

  • Tapinarof cream, 1% — DRUG
    Tapinarof cream, 1%: Applied topically once daily to lesions on participant's skin during the Double-Blind period. During the Open-Label Period, it will be applied once daily to lesions, as needed.
  • Vehicle Cream — DRUG
    Applied topically once daily to lesions on participant's skin during the Double-Blind period.

Study Details

The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.

Key Dates

Start date
Dec 29, 2025
Status verified
Feb 2026
Primary completion
Jan 31, 2028
Completion
Jan 31, 2028

Study Design

Enrollment
180 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Tapinarof cream
    Tapinarof cream, 1%, applied topically once daily
  • Placebo Comparator: Vehicle cream
    Vehicle cream is applied topically once daily for up to 8-weeks.

Primary Outcome Measure

Percentage of participants who have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement from Baseline to Week 8 [ Time Frame: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks. ]

Central Contacts

Locations (37)

FacilityCityStateZIPSite coordinators
AllerVie Clinical ResearchBirminghamAlabama35209
Weily Soong (PRINCIPAL_INVESTIGATOR)
Dermatology Trial AssociatesBryantArkansas72022
Dowling Stough (PRINCIPAL_INVESTIGATOR)
Dermatology Research AssociatesLos AngelesCalifornia90045
Howard Sofen (PRINCIPAL_INVESTIGATOR)
Integrative Skin Science and ResearchSacramentoCalifornia95815
Raja Sivamani (PRINCIPAL_INVESTIGATOR)
Allergy and Asthma Medical Group and Research CenterSan DiegoCalifornia92123
Bob Geng (PRINCIPAL_INVESTIGATOR)
Clinical Trials Research InstituteThousand OaksCalifornia91320
Navid Ezra (PRINCIPAL_INVESTIGATOR)
Clarity DermatologyCastle RockColorado80109
James Daniel Jensen (PRINCIPAL_INVESTIGATOR)
Skin Care Research, LLC.Boca RatonFlorida33486
Ann Mazor Reed (PRINCIPAL_INVESTIGATOR)
APEX Clinical TrialsJacksonvilleFlorida32256
Pearl Kwong (PRINCIPAL_INVESTIGATOR)
TruDerm ResearchWellingtonFlorida33449
Andleeb Usmani (PRINCIPAL_INVESTIGATOR)
Cleaver Medical Group Dermatology, IncCummingGeorgia30040
Weston Waxweiler (PRINCIPAL_INVESTIGATOR)
Ada West ResearchMeridianIdaho83646
Elizabeth Swanson (PRINCIPAL_INVESTIGATOR)
Endeavor Health Clinical Trials CenterSkokieIllinois60077
Joel Joyce (PRINCIPAL_INVESTIGATOR)
Dawes Fretzin Clinical Research Group, LLCIndianapolisIndiana46250
Kenneth Dawes (PRINCIPAL_INVESTIGATOR)
The Indiana Clinical Trials Center, PCPlainfieldIndiana46168
Scott Guenthner (PRINCIPAL_INVESTIGATOR)
Equity Medical, LLCBowling GreenKentucky42104
James Allred (PRINCIPAL_INVESTIGATOR)
Lawrence J Green, MD LLCRockvilleMaryland20850
Lawrence Green (PRINCIPAL_INVESTIGATOR)
Oakland Hills DermatologyAuburn HillsMichigan48326
Christofer Buatti (PRINCIPAL_INVESTIGATOR)
Minnesota Clinical Study CenterNew BrightonMinnesota55112
Steven Kempers (PRINCIPAL_INVESTIGATOR)
SKY Integrative Medical CenterRidgelandMississippi39157
Jasmine Hollinger (PRINCIPAL_INVESTIGATOR)
MediSearch Clinical TrialsSaint JosephMissouri64506
Melody Stone (PRINCIPAL_INVESTIGATOR)
Skin Cancer and Dermatology InstituteRenoNevada89509
Michael Heaphy (PRINCIPAL_INVESTIGATOR)
Forest Hills Dermatology GroupKew GardensNew York11415
Jeffrey Weinberg (PRINCIPAL_INVESTIGATOR)
Bobby Buka MD, PCNew YorkNew York10012
Andrew Peranteau (PRINCIPAL_INVESTIGATOR)
Equity Medical, LLCThe BronxNew York10455
Alissa McInerney (PRINCIPAL_INVESTIGATOR)
The University of North Carolina Dermatology and Skin Cancer CenterChapel HillNorth Carolina27516
Donna Culton (PRINCIPAL_INVESTIGATOR)
Cincinnati Children's Hospital Medical CenterCincinnatiOhio45229
Kalyani Marathe (PRINCIPAL_INVESTIGATOR)
Dermatologists of Central States, LLCFairbornOhio45324
Craig Rohan (PRINCIPAL_INVESTIGATOR)
Allergy Asthma and Clinical Research CenterOklahoma CityOklahoma73120
Martha Tarpay (PRINCIPAL_INVESTIGATOR)
Oregon Dermatology and Research CenterPortlandOregon97210
Phoebe Rich (PRINCIPAL_INVESTIGATOR)
Oregon Health & Science UniversityPortlandOregon97239
Tracy Funk (PRINCIPAL_INVESTIGATOR)
Medical University of South CarolinaCharlestonSouth Carolina29425
Lara Wine Lee (PRINCIPAL_INVESTIGATOR)
National Allergy and Asthma Research, LLC.North CharlestonSouth Carolina29420
John Ramey (PRINCIPAL_INVESTIGATOR)
The University of Texas Health Science Center at HoustonBellaireTexas77401
Adelaide Hebert (PRINCIPAL_INVESTIGATOR)
Dermatology Treatment and Research CenterDallasTexas75230
Ross Radusky (PRINCIPAL_INVESTIGATOR)
Stryde Research - Epiphany DermatologySouthlakeTexas76092
Ronald Todd Plott (PRINCIPAL_INVESTIGATOR)
Dermatology Specialists of SpokaneSpokaneWashington99202
Katherine Reed (PRINCIPAL_INVESTIGATOR)

Find similar trials in Birmingham, AL

Related Studies